Post-earnings recap
Reported
Wed, Jul 22, 2026
EPS actual
$4.25
EPS est.
$4.08
EPS surprise
+4.17%
1-day move
-0.67%
Medpace Holdings reported better-than-expected earnings per share, but did not provide revenue figures or guidance. The stock reacted negatively, declining by 0.67%, which may indicate investor caution despite the earnings beat. The lack of revenue data and management commentary could contribute to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.25 | $4.00 | +4.17% |
| Revenue | — | $690M | — |
No transcript is on record, so the analysis is based on numerical results only.
Medpace Holdings, Inc. is a leading clinical research organization that provides comprehensive services to the pharmaceutical and biotechnology industries. As part of the health care sector, Medpace plays a crucial role in advancing medical research and drug development, which is increasingly important as the demand for innovative treatments grows.
Last quarter
In Q1 2026, Medpace reported an EPS of $4.28, significantly beating expectations of $3.74. However, the stock declined by 1.25% the following day, indicating market caution despite the strong earnings.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+11.99%
Avg 1-day reaction
-1.02%
Analysts are generally optimistic about Medpace's upcoming earnings, expecting continued strong performance based on historical trends. The consensus EPS and revenue estimates suggest confidence in the company's growth trajectory.
Bull case
If Medpace exceeds the EPS estimate of $4.00, it could reinforce investor confidence and lead to a positive stock reaction, especially given its history of beating earnings expectations.
Bear case
Conversely, if the company fails to meet the consensus estimates, it could raise concerns about its growth sustainability, leading to a potential decline in stock price.
Key metrics to watch
EPS
$4.00Earnings per share is a key indicator of profitability and helps gauge the company's financial health.
Revenue
$690MRevenue growth reflects the company's ability to attract clients and expand its service offerings.
The print will turn on these.
Q1
Will Medpace's EPS exceed the consensus estimate of $4.00?
A beat on EPS would validate the company's strong performance and could lead to a positive stock reaction.
Q2
What guidance will management provide regarding future revenue growth?
Investors will be looking for insights into the company's growth strategy and potential challenges ahead.
—
Est. EPS
$4.19
Est. Rev
$1.2B
Impl. Move
±16.2%
Why consensus could be wrong
The consensus may underestimate Medpace's ability to leverage new client contracts, which could drive revenue growth beyond current expectations.
Supporting evidence
Historical performance shows a consistent ability to beat EPS estimates.
The options market is pricing a significant move, indicating potential for a larger-than-expected reaction.
Recent investments in technology could enhance operational efficiency and attract more clients.
Key risk
If revenue growth significantly outpaces expectations, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will indicate whether Medpace can maintain its growth trajectory amidst increasing competition in the life sciences sector.
Bull confirmed if
An EPS of $4.20 or higher would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS below $3.80 would raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±20.52%
Historical Avg
±1.1%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±20.5% while MEDP has averaged ±1.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
80.4%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$31.9M
51,231 sh
1 insider
Net
$31.9M
Net selling
Most Active Insiders· 4 open-market trades
$31.9M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
91.16%
of float
Insider
18.74%
of float
Holders
921
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
2,498,248 sh · $1.5B
8.95%
1.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Medpace beats expectations, history suggests the stock could rise around 1.49% on the first day, confirming strong operational momentum.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
Should the company miss estimates, history indicates a potential decline of around 0.46%, raising concerns about its growth outlook.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Sep 29, 2026 · @ $621.02
26,701 sh
$16.6M
Sep 30, 2026 · @ $625.47
21,966 sh
$13.7M
Sep 28, 2026 · @ $620.07
2,410 sh
$1.5M
Sep 25, 2026 · @ $620.60
154 sh
$95,572.40
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Price (T.Rowe) Associates Inc
2,069,677 sh · $1.3B
7.42%
614.9%
AQR Capital Management, LLC
1,278,935 sh · $772.8M
4.58%
-5.5%
Vanguard Portfolio Management LLC
1,133,357 sh · $684.8M
4.06%
1.0%
Vanguard Capital Management LLC
1,026,820 sh · $620.5M
3.68%
1.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 15, 2026 · disclosed May 28, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.